| INTRODUC TI ON
Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease characterized by systemic inflammation, persistent synovitis, and joint destruction, with a global prevalence of approximately 0.24%. 1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The efficacy and safety of tofacitinib 5 and 10 mg twice daily, as monotherapy or with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), mainly methotrexate, in patients with moderately to severely active RA, have been demonstrated in global Phase 2, 2-6 Phase 3, [7] [8] [9] [10] [11] [12] and Phase 3b/4 13 studies of up to 24 months duration, and in long-term extension (LTE) studies with up to 114 months of observation. [14] [15] [16] The European League Against Rheumatism and American College of Rheumatology (ACR) recommend tofacitinib as a treatment option after inadequate response to csDMARDs. 17, 18 Guidelines from the AsiaPacific League of Associations for Rheumatology support the use of tofacitinib in patients who have an inadequate response to biologic DMARDs (bDMARDs). 19 However, understanding of the efficacy and safety of tofacitinib in patients with RA from the Asia-Pacific region is largely based on post-hoc analyses of data from patients enrolled in individual countries within the global LTE studies, including sub-populations from Korea, 20 Japan, 16 and China. 21 These studies indicated that tofacitinib had a stable safety profile and sustained efficacy within each Asia-Pacific country, although an increased risk of herpes zoster (HZ) was observed in Japan and Korea vs global studies. It is of particular interest to assess RA therapies within the Asia-Pacific region, given the demographic differences between Asia-Pacific and Western patients with RA that may affect efficacy, and the increased background prevalence of certain infections (eg tuberculosis and hepatitis B and C) and malignancies (eg T-cell and natural killer-cell lymphomas) within the Asia-Pacific region vs Western countries.
19
In this post-hoc analysis, we report tofacitinib efficacy and safety in patients with RA from the Asia-Pacific region as a combined group within the global clinical studies. This pooled analysis included a larger number of patients than country-specific sub-populations to yield more precise estimates of efficacy and safety.
| ME THODS

| Patients
This post-hoc analysis included data from patients with RA enrolled in global clinical studies of tofacitinib from eight Asia-Pacific countries: China, India, Japan, Korea, Malaysia, the Philippines, Taiwan and Thailand. Detailed inclusion and exclusion criteria have been previously published. 3, 4, [6] [7] [8] [9] [10] [11] [12] 14, 16, 22, 23 Briefly, patients were aged ≥18, or ≥20 years in Japan, with an active RA diagnosis based on the ACR 1987 Revised Criteria. Key exclusion criteria included serious chronic or recurring infections, active or inadequately treated infection with Mycobacterium tuberculosis, a history of recurrent HZ, disseminated HZ, or disseminated herpes simplex, or a history of malignancy, except adequately treated squamous cell or basal cell skin cancers or cervical carcinoma in situ.
| Study designs
Patients from the Asia-Pacific region participated in 13 stud- Details of the individual study designs have been previously published and are summarized in Appendix S1. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] 14, 16, [22] [23] [24] [25] [26] [27] [28] All studies were conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines. The study protocols were approved by the Institutional Review Boards and/or Independent Ethics Committee at each study center. All patients provided written informed consent.
| Efficacy endpoints
Efficacy data were pooled from three Phase 2 (NCT00550446, NCT00603512, NCT00687193) and five Phase 3 (ORAL Solo, ORAL Scan, ORAL Sync, ORAL Standard, ORAL Step) randomized, placebo-controlled, double-blind studies which included patients with a prior inadequate response to DMARDs (hereafter termed the "P2/3
Conclusion: In Asia-Pacific patients, tofacitinib improved signs/symptoms over 24 months. Safety over 92 months was generally consistent with global tofacitinib studies; however, infection IRs were higher in Asia-Pacific patients.
K E Y W O R D S
clinical aspects, drug treatment, rheumatoid arthritis population"). To assess efficacy in a more homogenous patient popu- 
| Safety endpoints
Safety data were pooled from all 13 Phase 1, Phase 2, Phase 3, and LTE studies of tofacitinib which included patients with RA from the Asia-Pacific region and included up to 92 months of tofacitinib exposure (hereafter termed the "P123LTE population" 
| Statistical analysis
Efficacy analyses were based on the full analysis set of each study, which included all patients who were randomized and received ≥1 dose of study medication. Seven patients from the Philippines en- 
| RE SULTS
| Patients
The P123LTE population included 1464 patients from the AsiaPacific region. Of these, 790 received an average total daily dose (TDD) of 5 mg twice daily and 674 received an average TDD of tofacitinib 10 mg twice daily. The largest number of patients were enrolled from Japan (n = 556), followed by Korea (n = 291), China (n = 213), India (n = 197), Thailand (n = 64), the Philippines (n = 61), Malaysia (n = 46), and Taiwan (n = 36).
Across all tofacitinib doses at baseline, mean age was 50.5 years, 86.9% of patients were female, mean disease duration was 7.1 years, mean tender and swollen joint counts were 21.3 and 13.8, respectively, and most patients (72.1%) were receiving concomitant corticosteroid treatment. Baseline demographics and characteristics were generally similar between patients treated with tofacitinib 5 and 10 mg twice daily, with the exception that mean ESR (54.5 vs 64.0 mm/h, respectively) was lower in the tofacitinib 5 mg twice daily group (Table 1) .
| Efficacy
Efficacy data are reported for the 1022 patients in the P2/3 population, of whom 397 were randomized to receive tofacitinib 5 mg twice daily, 382 to tofacitinib 10 mg twice daily, and 243 to placebo.
At month 3, greater response rates were observed for tofacitinib BID, twice daily; bDMARD, biologic DMARD; BMI, body mass index; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; csDMARD, conventional synthetic DMARD; DAS28-4, Disease Activity Score in 28 joints; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; LTE, long-term extension; MTX, methotrexate; P, Phase; RF, rheumatoid factor; SD, standard deviation; TNFi, tumor necrosis factor inhibitor. The average total daily dose (TDD) of tofacitinib was calculated: patients were assigned to the 5 mg BID group if the TDD was <15 mg/d and to the 10 mg BID group if it was ≥15 mg/d. The P123LTE population (Asia-Pacific) included patients from one Phase 1 study, four Phase 2 studies, six Phase 3 studies, and two LTE studies. The global population (Asia-Pacific and all other study locations) included patients from two Phase 1 studies, 10 Phase 2 studies, six Phase 3 studies, and two LTE studies.
a
The number of patients with baseline data available was variable across characteristics. ( Figure 1 ). ACR response rates were maintained through month 24 for patients who were randomized to receive tofacitinib 5 and 10 mg twice daily ( Figure 1 ); greater response rates were observed with tofacitinib 10 vs 5 mg twice daily. By month 9, patients who advanced to tofacitinib from placebo at month 3 or month 6 achieved similar ACR responses to those randomized to tofacitinib from baseline.
At baseline, mean DAS28-4(ESR) scores were similar for patients randomized to receive tofacitinib 5 or 10 mg twice daily and placebo AE, adverse event; BID, twice daily; CI, confidence interval; IR, incidence rate; LTE, long-term extension; MACE, major adverse cardiovascular event; NMSC, non-melanoma skin cancer; P, Phase; PY, patient-years; SAE, serious adverse event.
The average total daily dose (TDD) of tofacitinib was calculated: patients were assigned to the 5 mg BID group if the TDD was <15 mg/d and to the 10 mg BID group if it was ≥15 mg/d. The P123LTE population (Asia-Pacific) included patients from one Phase 1 study, four Phase 2 studies, six Phase 3 studies, and two LTE studies. The global population (Asia-Pacific and all other study locations) included patients from two Phase 1 studies, 10 Phase 2 studies, six Phase 3 studies, and two LTE studies. respectively; Figure 2D ,E). Rates of CDAI remission and LDA continued to improve to month 24; higher rates were observed with tofacitinib 10 vs 5 mg twice daily.
At baseline, mean HAQ-DI scores were similar for patients randomized to receive tofacitinib 5 or 10 mg twice daily and placebo 
4.3]).
The most common serious infections were serious HZ (n = 32), TA B L E 3 Incidence rates (patients with event/100 patient-years) for confirmed changes in laboratory parameters (P123LTE population) ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice daily; CI, confidence interval; LTE, long-term extension; P, Phase; PY, patient-years; ULN, upper limit of normal. The average total daily dose (TDD) of tofacitinib was calculated: patients were assigned to the 5 mg BID group if the TDD was <15 mg/d and to the 10 mg BID group if it was ≥15 mg/d. The P123LTE population (Asia-Pacific) included patients from one Phase 1 study, four Phase 2 studies, six Phase 3 studies, and two LTE studies.
The global population (Asia-Pacific and all other study locations) included patients from two Phase 1 studies, 10 Phase 2 studies, six Phase 3 studies, and two LTE studies.
pneumonia (n = 32), and tuberculosis (n = 24). In total, 250 cases of HZ (both serious and non-serious) were reported (IR: 5.9 [5.2, 6.7] ).
Of these, most involved a single dermatome (n = 232; 92.8%), four cases involved two adjacent dermatomes, two were disseminated cases, and 12 were multidermatomal (non-adjacent dermatomes or In Asia-Pacific patients with prior inadequate response to DMARDs, tofacitinib 5 and 10 mg twice daily provided greater improvements in RA signs and symptoms and physical function vs placebo at month 3, with improvements sustained through 24 months.
Improvements in efficacy endpoints in this pooled analysis were similar or even slightly higher than the range reported across the global Phase 3 studies up to 24 months. [7] [8] [9] [10] [11] [12] For example, ACR20 response rates (placebo-adjusted) with tofacitinib 5 and 10 mg twice daily were 41.7% and 50.4%, respectively, at month 3 in the P2/3
Asia-Pacific population, vs 19.1%-35.5% and 25.7%-42.6%, respectively, at month 3 across global Phase 3 studies (data on file). These differences in efficacy between populations may be explained by differences in patient characteristics, such as the lower proportion of Asia-Pacific patients who had previously received bDMARDs (12%)
vs the global population (20% 30 Similarly, an increased risk of HZ in patients from Japan vs the global population has also been reported with the Janus kinase inhibitor baricitinib. 31 The reported background incidence of HZ in the general population of Japan 32 is similar to the global population, 33, 34 but is higher in Japanese patients with RA. 35 Higher background incidence of HZ in the general population has been reported in a study in Korea 36 vs the global population. 33, 34 A genome-wide association study identified a single nucleotide polymorphism near IL-17RB associated with a faster rate of HZ onset and which was more common in East Asian (~17%) vs Caucasian (<0.2%) populations, which may explain some of these observed differences. 37 However, the reasons for these country-specific differences in HZ incidence following tofacitinib treatment require further investigation. Other factors, such as the proportion of patients who were vaccinated against HZ prior to the studies, may play a role in the regional differences observed in the incidence of HZ. 
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